Mankind Pharma Q2 Results FY27: PAT Rises 13.77% to Rs 581.95 Cr, Revenue Rs 3,145.22 Cr

Mankind Pharma Ltd (MANKIND) Q2 Results FY27 announced on 26 October 2026, covering the company's financial performance for the July to September quarter. Revenue stood at Rs 3,145.22 Cr against Rs 3,697.16 Cr a year earlier, and net profit rose to Rs 581.95 Cr from Rs 511.51 Cr. Mankind Pharma Q2 Results FY27 arrived on the results date with revenue and profit moving in opposite directions.

This Mankind Pharma Q2 Results results analysis covers the financial highlights, the business drivers behind the quarter, the FY27 outlook and the risks to watch. It starts with the Financial Highlights, where revenue, net profit and the YoY change for each are set out side by side.

Click Here – Get Free Investment Predictions

Mankind Pharma Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 3145.22 Cr	Rs 3697.16 Cr	-14.93% YoY
Net Profit (PAT)	Rs 581.95 Cr	Rs 511.51 Cr	+13.77% YoY

Source: company filing for Mankind Pharma Q2 Results FY27, 26 October 2026. Figures in Rs Crore.

Key Takeaways from Mankind Pharma Q2 Results: What Stands Out

• Revenue of Rs 3,145.22 Cr was down 14.93% YoY from Rs 3,697.16 Cr, the lower line in this quarter's numbers.
• Net profit of Rs 581.95 Cr was up 13.77% YoY from Rs 511.51 Cr, so YoY growth in profit came despite lower revenue.
• Net profit margin of 18.5% compares with 13.8% in the comparison quarter, which is simple arithmetic on net profit and revenue.
• Mankind Pharma Q2 Results FY27 also show revenue down 22.0% quarter on quarter from Rs 4,030.59 Cr, a sequential point worth tracking.
• The performance analysis below takes the revenue and net profit split further, one paragraph at a time.

Mankind Pharma Q2 Results FY27: Performance Analysis

Mankind Pharma reported revenue of Rs 3,145.22 Cr and net profit of Rs 581.95 Cr for the July to September 2026 quarter. Revenue fell 14.93% YoY while net profit rose 13.77% YoY. In this results analysis, the two lines moved in opposite directions, which is the central fact of the quarter.

Compared with the same quarter last year, revenue was lower by Rs 551.94 Cr, moving from Rs 3,697.16 Cr to Rs 3,145.22 Cr. Net profit moved the other way, from Rs 511.51 Cr to Rs 581.95 Cr. Mankind Pharma Q2 Results FY27 therefore show YoY growth in profit on a smaller revenue base.

Investors reading the quarterly results will also notice the sequential move, with revenue down 22.0% from Rs 4,030.59 Cr in the previous quarter. Subsequent disclosures will show how revenue evolves from here. The supplied data confirms the figures but does not establish a specific cause, so the business factors section covers the disclosed drivers.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Net Profit Growth – The business factors begin with net profit, which rose 13.8% year on year to Rs 581.95 Cr. This is the disclosed driver of the profit side of Mankind Pharma Q2 Results FY27, and it stands out because revenue moved lower over the same period.

Net Profit Margin – Net profit margin improved to 18.5% from 13.8% in the comparison quarter. This margin shift explains how a higher net profit sat alongside lower revenue in the quarterly results, and it is the second disclosed factor.

Profit Against Revenue – Revenue of Rs 3,145.22 Cr was below the Rs 3,697.16 Cr of a year earlier, while net profit of Rs 581.95 Cr was above Rs 511.51 Cr. Together the two lines show profit growing faster than the revenue base moved.

FY27 Outlook After Mankind Pharma Q2 Results

The FY27 outlook will depend on how revenue and net profit develop in the quarters ahead. After Mankind Pharma Q2 Results, the results analysis shows one quarter in which net profit grew 13.77% YoY while revenue declined 14.93% YoY, and a single quarter does not settle the full year.

FY27 full-year results will depend on subsequent quarters and disclosed sector conditions. Readers tracking net profit can use the Univest Screener to follow later filings from the company. The risks that could shape those filings are set out next, starting with the revenue trend.

Key Risks to Watch After Mankind Pharma Q2 Results FY27

Revenue Decline Year on Year

Revenue declined 14.9% year on year to Rs 3,145.22 Cr in the latest quarter. If lower revenue continues, YoY growth in profit may become harder to sustain, so the next filing deserves a close read.

Sequential Revenue Drop

Revenue was down 22.0% quarter on quarter from Rs 4,030.59 Cr. Mankind Pharma Q2 Results FY27 therefore show a sharp step down from the previous quarter, which readers can track in later disclosures.

Lower Return on Equity

Return on equity declined to 12.69% in FY26 from 16.98% in FY25. This earlier annual trend sits behind the quarter's net profit and remains a point to watch on the Univest app.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

Mankind Pharma Q2 Results FY27 show revenue of Rs 3,145.22 Cr, down 14.93% YoY, and net profit of Rs 581.95 Cr, up 13.77% YoY. These quarterly results mix a lower top line with a higher bottom line. Investors should consult a SEBI-registered advisor before acting on Mankind Pharma Q2 Results.

Frequently Asked Questions on Mankind Pharma Q2 Results FY27

What are Mankind Pharma Q2 Results FY27?

Ans. Mankind Pharma Q2 Results FY27 cover the July to September 2026 quarter, with revenue of Rs 3,145.22 Cr and net profit of Rs 581.95 Cr, as set out in the Quick Answer.

What is the results date for Mankind Pharma Q2 Results FY27?

Ans. Mankind Pharma declared its Q2 FY27 results on 26 October 2026, which is the results date, while the intro paragraphs place that date alongside revenue and net profit for the quarter.

What revenue was reported in Mankind Pharma Q2 Results FY27?

Ans. Mankind Pharma reported revenue of Rs 3,145.22 Cr in Q2 FY27, compared with Rs 3,697.16 Cr a year earlier, as the Performance Analysis section explains.

What net profit was reported in Mankind Pharma Q2 Results FY27?

Ans. Mankind Pharma reported net profit of Rs 581.95 Cr in Q2 FY27, compared with Rs 511.51 Cr a year earlier, which means profit rose while revenue fell, as covered in Key Takeaways.

How much YoY growth did revenue show in Mankind Pharma Q2 Results FY27?

Ans. Revenue showed a 14.93% YoY decline to Rs 3,145.22 Cr, so there was no YoY growth on the top line, while the Financial Highlights table sets out the exact comparison.

Did net profit rise or fall in Mankind Pharma Q2 Results?

Ans. Net profit rose 13.77% YoY to Rs 581.95 Cr in Mankind Pharma Q2 Results, which means profit grew even as revenue declined, a split the Performance Analysis section examines in detail.

What was the net profit margin in Mankind Pharma Q2 Results FY27?

Ans. Net profit margin improved to 18.5% from 13.8% in the comparison quarter, so profit made up a larger share of revenue, as the Key Business Factors section notes.

Where does Mankind Pharma Q2 Results FY27 show the quarter on quarter change?

Ans. Revenue was down 22.0% quarter on quarter from Rs 4,030.59 Cr, alongside the YoY decline, and the Key Risks section lists this sequential drop as a point to watch.

What business factors shaped Mankind Pharma Q2 Results FY27?

Ans. The disclosed factors are net profit growth of 13.8% to Rs 581.95 Cr and a better net profit margin of 18.5%, which the Key Business Factors section describes in more detail.

What are the key risks after Mankind Pharma Q2 Results FY27?

Ans. The risks are the 14.9% YoY revenue decline, the 22.0% sequential drop and a return on equity of 12.69% in FY26, all of which the Key Risks section expands on.

What is the outlook after Mankind Pharma Q2 Results?

Ans. The FY27 outlook depends on subsequent quarters, since one quarter of 13.77% net profit growth does not settle the year, as the FY27 Outlook section explains for readers.

Where can I find the complete Mankind Pharma Q2 Results FY27 data?

Ans. The complete figures appear in the Financial Highlights table above, while the Univest Screener lets readers follow later filings from Mankind Pharma and compare each quarterly result.